[The mechanism of the antiarrhythmic action of dalargin in experimental myocardial ischemia].

Abstract

It has been found that injection of dalargin before the occlusion of the left anterior coronary artery prevents an increase of cAMP content in the myocardium and blood plasma. In the myocardium of rats given dalargin before acute myocardial ischemia, the content of cGMP was increased and the level of somatostatin was reduced. It is assumed that the increase of the content of cGMP and the reduction of cAMP and somatostatin levels in the myocardium play an important role in antiarrhythmic action of dalargin.

• Authors: L N Maslov, Iu B Lishmanov
• Journal: Eksperimental'naia i klinicheskaia farmakologiia (Eksp Klin Farmakol) 1992 Mar-Apr Vol. 55 Issue 2 Pg. 25-8 ISSN: 0869-2092 [Print] Russia (Federation)
• Vernacular Title: K mekhanizmu antiaritmicheskogo deĭstviia dalargina pri éksperimenal'noĭ ishemii miokarda.
• PMID: 1358376 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Anti-Arrhythmia Agents
• Nucleotides, Cyclic
• Somatostatin
• Enkephalin, Leucine-2-Alanine
• enkephalin-Leu, Ala(2)-Arg(6)-

Topics

• Animals
• Anti-Arrhythmia Agents (pharmacology, therapeutic use)
• Arrhythmias, Cardiac (etiology, prevention & control)
• Disease Models, Animal
• Drug Evaluation, Preclinical
• Electrocardiography (drug effects)
• Enkephalin, Leucine-2-Alanine (analogs & derivatives, pharmacology, therapeutic use)
• Heart (drug effects)
• Male
• Myocardial Ischemia (complications, drug therapy, metabolism)
• Myocardium (chemistry, metabolism)
• Nucleotides, Cyclic (analysis)
• Rats
• Somatostatin (analysis)